Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) went lower by -16.9978% to close at $ 0.3384. The company exchanged total volume of 4.14 million shares throughout course of last trade however it holds an average trading capacity of 843.71 thousand shares. Shares of company began trading at $0.4200 climbed to high of $0.4200 touched the low of $0.3200.
The company is trading below its 50-day moving averages of 0.4533 and down from 200-day moving averages of 1.0942. The firm has its price to sale ratio was 29.9758.
The average true range of Northwest Biotherapeutics, Inc.’s (NWBO) is recorded at 0.05 and the relative strength index of the stock stands 24.03. The stock price is going below to its 52 week low with -9.52% and lagging behind from its 52 week high with -96.06%. Analyst recommendation for this stock stands at 2.00. A look on the firm performance, its monthly performance is -26.19% and a quarterly performance of -58.73%. The stock price is trading downbeat from its 200 days moving average with -82.01% and down from 50 days moving average with -32.93%.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) dropped -1.52% and closed the trade at $ 3.88. The company recorded a trading capacity of 832.86 thousand shares above its three months average daily volume of 293.86 thousand shares. During the last trade, shares reached to high price of $4.19 and touched the low price of $3.82. The stock’s 50-day moving average is noted at $3.04 and its 200-day moving average is stands at $2.44.
Additionally, the company has EPS of -0.32. The company has market capitalization of $169.74M.
According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. Currently shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “4” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “0” brokerage firms. “0” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 1 based on consensus of the brokerage firms issuing ratings.
Corbus Pharmaceuticals Holdings, Inc.’s (CRBP) has price-to-cash ratio of 7.53 and price to sale ratio of 127.38. A look on the firm performance, its monthly performance is 36.62% and a quarterly performance of 52.76%. The stock price is moving up from its 20 days moving average with 25.97% and isolated positively from 50 days moving average with 28.99%.